Literature DB >> 27212866

Amiodarone toxicity: An underdiagnosed entity.

Joseph Xavier1, Maruti Yamanappa Haranal1, Shashidhar Ranga Reddy2, Sridhar Melagiriyappa3.   

Abstract

Entities:  

Year:  2016        PMID: 27212866      PMCID: PMC4867816          DOI: 10.4103/0974-2069.180671

Source DB:  PubMed          Journal:  Ann Pediatr Cardiol        ISSN: 0974-5149


× No keyword cloud information.
Sir, Amiodarone is the most commonly used drug in cardiac intensive care unit (ICU) for tachyarrhythmias. Elimination half-life of amiodarone is long and variable; potential for drug interaction exists even when drugs are administered after the discontinuation of amiodarone therapy. Amiodarone toxicity can be accentuated by drugs that interact with its metabolism and elimination such as fluconazole and other drugs. It carries arrhythmogenic potential including life-threatening heart blocks and increased resistance to cardioversion.[123] Small children are more prone to adverse effects of amiodarone, particularly if they are in a hemodynamically compromised status, as is reported by Saharan et al.[4] Although, procainamide has been mooted as a superior alternative to amiodarone, when treating refractory supraventricular tachyarrhythmias by Chang et al.,[5] their adverse effects remain the same. Amiodarone is still “the drug of choice” for arrhythmias in practice today. We report a case of amiodarone toxicity in pediatric cardiac surgery. A 10-month-old, severely undernourished, severely cyanosed spelling baby, weighing 4 Kg, underwent intracardiac repair for Tetralogy of Fallot [ventricular septal defect (VSD) closure + infundibular resection + transannular patch], came off bypass in sinus bradycardia, and was started on atrioventricular (AV) sequential pacing. Inotropic supports were: Milrinone (0.3 mcg/kg/min) and noradrenaline (0.05 mcg/kg/min). On the first postoperative day (POD), the child developed right ventricular dysfunction and junctional ectopic tachyarrhythmia (JET) [Figure 1]. The patient responded to intravenous (IV) amiodarone bolus (5 mg/kg), followed by maintenance dose (10 mg/kg/day), and reverted to sinus rhythm. Amiodarone was later continued orally. Routine blood culture grew Candida albicans, for which antifungal IV fluconazole 10 mg/kg/day was given as a single dose infused over 1 h and then continued orally. The child was extubated on the fifth POD, in sinus rhythm. Two-dimensional echocardiography showed improved ventricular function and inotropes were weaned off. On the ninth POD, while removing the internal jugular vein (IJV) line, there was a witnessed bradycardia and arrest needing cardiopulmonary resuscitation (CPR). This precipitous rhythm change was most probably vasovagal bradycardia, leading to AV dissociation with slow ventricular escape rate [Figure 2] not responding to ventricular or AV sequential epicardial pacing [Figure 3]. Circulation was maintained by cardiac massage for 45 min, by which time in response to emergency drugs adrenaline and atropine, the ventricular escape rhythm was stabilized at a higher rate of 100 beats/min. New epicardial pacing wires (both atrial and ventricular) were placed through a subxiphoid exploration, but proved to be ineffective. The child was back on the ventilator with femoral arterial and venous lines were reinserted and on inotropes: Adrenaline (0.05 mcg/kg/min) and isoprenaline (0.1 mcg/kg/min). In the next 48 h, there were several episodes of slow ventricular escape rhythm needing cardiac compressions, IV atropine, and adrenaline purge. After 48 h, the heart responded to epicardial AV sequential pacing. A week after stopping amiodarone (15th POD), it reverted to sinus rhythm and continued to be normal [Figure 4].
Figure 1

Junctional ectopic tachycardia (JET)

Figure 2

AV dissociation with ventricular escape rhythm

Figure 3

Inability to capture pacing with maximum output (heart rate — 100 beats/min)

Figure 4

Sinus rhythm (after a week of stopping amiodarone)

Junctional ectopic tachycardia (JET) AV dissociation with ventricular escape rhythm Inability to capture pacing with maximum output (heart rate — 100 beats/min) Sinus rhythm (after a week of stopping amiodarone) In our case, we can clearly see the bradyarrhythmia not responding to epicardial pacing in a scenario where amiodarone and fluconazole have been used simultaneously for more than 1 week. We could not get an amiodarone blood level done as no laboratory was equipped to do so. IV pacing was not technically possible.

CONCLUSION

Amiodarone toxicity can result in AV dissociation and life threatening heart blocks refractory to pacing. One has to be cautious in infants when considering continued amiodarone therapy, and even more careful while starting other drugs that interact and prolong the action of amiodarone such as fluconazole in this case.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  5 in total

1.  Amiodarone versus procainamide for the acute treatment of recurrent supraventricular tachycardia in pediatric patients.

Authors:  Philip M Chang; Michael J Silka; David Y Moromisato; Yaniv Bar-Cohen
Journal:  Circ Arrhythm Electrophysiol       Date:  2010-03-01

2.  Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias.

Authors:  R N Fogoros; K P Anderson; R A Winkle; C D Swerdlow; J W Mason
Journal:  Circulation       Date:  1983-07       Impact factor: 29.690

3.  Amiodarone: pharmacology and antiarrhythmic and adverse effects.

Authors:  G V Naccarelli; R L Rinkenberger; A H Dougherty; R A Giebel
Journal:  Pharmacotherapy       Date:  1985 Nov-Dec       Impact factor: 4.705

4.  Amiodarone in long term management of refractory cardiac tachyarrhythmias.

Authors:  W F Lubbe; C J Mercer; A H Roche; J B Lowe
Journal:  N Z Med J       Date:  1981-01-28

5.  Cardiovascular collapse during amiodarone infusion in a hemodynamically compromised child with refractory supraventricular tachycardia.

Authors:  Sunil Saharan; Seshadri Balaji
Journal:  Ann Pediatr Cardiol       Date:  2015 Jan-Apr
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.